Alnylam Pharmaceuticals, Inc. (ALNY)
Nasdaq · Healthcare · Biotechnology
$219.89+0.08%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $29.4B
- P/E (trailing)
- 37.1
- Forward P/E
- 17.6
- 52-week range
- $197.81 – $495.55
- 52-week change
- −52.19%
- EPS (trailing)
- $5.93
- Analyst rating
- 1.7 Buy
- Next earnings
- Oct 29, 2026
Fiscal year to Dec 2025
- Revenue
- $3.7B (+65.19%)
- Net income
- $314M
- Operating margin
- 13.5%
- Diluted EPS
- $2.33
- Free cash flow
- $465M
From the company’s annual report on SEC EDGAR.
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products in Phase 3 trial, such as Nucresiran for ATTR amyloidosis; Zilebesiran for hypertension; Cemdisiran for myasthenia gravis, paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and Elebsiran for hepatitis D virus infections. In addition, the company is developing various products in Phase 2 trial, including Rapirosiran for metabolic dysfunction-associated steatohepatitis; ALN-ANG3 for diabetic kidney disease; ALN-4324 for type 2 diabetes mellitus; Mivelsiran for cerebral amyloid angiopathy, as well as in Phase 1 trial for Alzheimer's disease; and ALN-6400 for bleeding disorders.
Headquarters: Cambridge, United States · 2,500 employees · alnylam.com